JAK inhibitors have expanded options for managing alopecia areata, but questions remain around patient selection, monitoring, and long-term use. In this new AMJ Dermatology article, Adelaide Hebert and Karan Lal share evidence and real-world cases from a recent CME seminar to help dermatologists navigate these decisions in daily practice.
